Management of Type-2 Diabetic Patients Treated With Insulin During the Ramadan
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
Fasting during the Ramadan is one of the five pillars of Islam and is a mandatory duty for
all healthy adult Muslims. Fasting is considered safe in young healthy subjects but it can
induce harmful effects and complications in patients with diabetes. Several studies have
demonstrated that patients with type 2 diabetes are prone to hypo and hyper glycemia during
fasting. When treating diabetic patients with a treatment guideline the rate of these
complications can be reduced. Little data is available on patients with type 2 diabetes
treated with insulin. The investigators therefore propose to assess the effect of a protocol
containing detemir (levemir) and a premix of insulin aspart (NovoMix70) on glucose control in
patients with type 2 diabetes during the Ramadan and to compare this regimen to the standard
care patients receive during this period. The investigators assume that patients receiving
the intervention will have better glucose control during the Ramadan compared to patients
receiving the standard care. As approximately 45 million Muslims suffer from type 2 diabetes
and most of them fast during the Ramadan the results of this intervention may be significant
and may improve the care of these patients allowing Muslims to respect their religious
obligations without compromising their health.